Bayer Settles Roundup Cancer Suits for Over $10 Billion
In one of the largest civil settlements in U.S. history, Bayer agreed Wednesday to pay more than $10 billion to resolve around 95,000 cases claiming its glyphosate-based weedkiller Roundup causes cancer.
The deal will still allow Bayer to sell Roundup without adding any warnings, The New York Times reported. It comes after three juries in early, high-profile trials awarded more than $2.4 billion to plaintiffs who developed non-Hodgkin's lymphoma after long term Roundup use.
"Even Bayer's billions can't magically make glyphosate's well-documented links to cancer disappear," Center for Biological Diversity (CBD) senior scientist Nathan Donley said in a statement reported by The Guardian. "Bayer only settled after three multi-million-dollar verdicts over the past year from jurors who, unlike the EPA, wisely put more trust in the safety assessments of independent scientists than in Monsanto/Bayer's confidential reviews of its own product."
Even as they settle, @Bayer officials continue to deny Monsanto’s glyphosate herbicides cause cancer. “The extensive body of science indicates that Roundup does not cause cancer, and therefore, is not responsible for the illnesses alleged...”https://t.co/45xQPai62f— carey gillam (@careygillam) June 24, 2020
The debate over Roundup's safety is ongoing, The New York Times explained. In 2015, the World Health Organization's International Agency for Research on Cancer said that glyphosate could "probably" cause cancer, but other regulatory bodies, including the U.S. Environmental Protection Agency (EPA), have ruled it safe. However, critics point out that many of these safe rulings were based on studies provided by Monsanto, the company that developed and sold Roundup before it was acquired by Bayer in 2018.
Per the terms of the settlement, the question of Roundup's safety will now pass to an independent "Class Science Panel," U.S. Right to Know (USTK) reported. The panel will decide if Roundup use can cause non-Hodgkin lymphoma and at what levels of exposure. Both Bayer and any future plaintiffs in the class action lawsuit will be bound by its findings. Until those findings are released, a process likely to take years, plaintiffs cannot bring any claims or seek punitive damages.
In the deal, Bayer earmarked $8.8 billion to $9.6 billion to settle 75 percent of current cases and $1.25 billion for any future claims. The three cases already decided by juries, currently in appeal, are not included.
Both plaintiff lawyers and Bayer celebrated the agreement.
"After years of hard fought litigation and a year of intense mediation I am glad to see our clients will now be compensated," Mike Miller of the Miller law firm told USRTK.
Bayer, meanwhile, seemed eager to escape the shadow cast on the company after it acquired both Monsanto and its legal challenges. Bayer's stock price plummeted after the three juries ruled against it, The New York Times pointed out.
"First and foremost, the Roundup™ settlement is the right action at the right time for Bayer to bring a long period of uncertainty to an end," Bayer CEO Werner Baumann said in a statement.
Bayer has reached a series of agreements to resolve major legacy Monsanto litigation in the U.S.— Bayer AG (@Bayer) June 24, 2020
Learn more: https://t.co/crqNTLIkVd
However, not all the plaintiffs bringing claims against Bayer agreed to the settlement. The company still faces at least 30,000 claims, according to The New York Times.
"This is nothing like the closure they're trying to imply," Fletch Trammell, a Houston-based lawyer who represents 5,000 of the people bringing those claims, told The New York Times. "It's like putting out part of a house fire."
Also on Wednesday, Bayer settled two other lawsuits inherited from Monsanto, The Guardian reported. First, it will pay $400 million to settle claims related to dicamba, another herbicide that can drift to other crops and kill them.
"The settlement announced today is an important step to making things right for the farmers who just want to be able to put food on the table of America and the world," lawyer Joseph Peiffer of Peiffer Wolf law firm, which represents farmers with dicamba claims, told USRTK of the second herbicide settlement.
Bayer will pay a further $820 million to settle "most" claims related to PCB, a toxic chemical that Monsanto produced until 1977 that contaminated U.S. water supplies, The Guardian reported.
- Man Who Developed Cancer After Roundup Use Awarded More ... ›
- Trump's EPA Backs Bayer's Appeal in Roundup Verdict Appeal ... ›
- More Monsanto Roundup Cancer Trials Expected to Be Postponed ... ›
- Former Monsanto CEO Ordered to Testify at Roundup Cancer Trial ... ›
- Roundup Cancer Settlement Hits Snag With Judge Over Future Plaintiffs' Rights - EcoWatch ›
In 2010, world leaders agreed to 20 targets to protect Earth's biodiversity over the next decade. By 2020, none of them had been met. Now, the question is whether the world can do any better once new targets are set during the meeting of the UN Convention on Biodiversity in Kunming, China later this year.
- Ocean Scientists Create Global Network to Help Save Biodiversity ... ›
- 5 Reasons Why Biodiversity Matters - EcoWatch ›
- 26 Organizations Working to Conserve Seed Biodiversity - EcoWatch ›
- The Top 10 Ocean Biodiversity Hotspots to Protect - EcoWatch ›
- New Platform Shows How to Protect Biodiversity and Save Planet ... ›
- These Scientists Are Listening to the Borneo Rainforest to Protect ... ›
EcoWatch Daily Newsletter
By Andrew Rosenberg
The first 24 hours of the administration of President Joe Biden were filled not only with ceremony, but also with real action. Executive orders and other directives were quickly signed. More actions have followed. All consequential. Many provide a basis for not just undoing actions of the previous administration, but also making real advances in public policy to protect public health, safety, and the environment.
- Here Are Biden's Day One Actions on Climate and Environment ... ›
- UCS Offers Science Advice for Biden Administration - EcoWatch ›
A first-of-its-kind study has examined the satellite record to see how the climate crisis is impacting all of the planet's ice.
- 'Ghost Forests' Are an Eerie Sign of Sea-Level Rise - EcoWatch ›
- Sea-Level Rise Takes Business Toll in North Carolina's Outer Banks ... ›
- Sea Level Rise Is Locked in Even If We Meet Paris Agreement ... ›
By Ana Maldonado-Contreras
- Your gut is home to trillions of bacteria that are vital for keeping you healthy.
- Some of these microbes help to regulate the immune system.
- New research, which has not yet been peer-reviewed, shows the presence of certain bacteria in the gut may reveal which people are more vulnerable to a more severe case of COVID-19.
You may not know it, but you have an army of microbes living inside of you that are essential for fighting off threats, including the virus that causes COVID-19.
How Do Resident Bacteria Keep You Healthy?<p>Our immune defense is part of a complex biological response against harmful pathogens, such as viruses or bacteria. However, because our bodies are inhabited by trillions of mostly beneficial bacteria, virus and fungi, activation of our immune response is tightly regulated to distinguish between harmful and helpful microbes.</p><p>Our bacteria are spectacular companions diligently helping prime our immune system defenses to combat infections. A seminal study found that mice treated with antibiotics that eliminate bacteria in the gut exhibited an impaired immune response. These animals had low counts of virus-fighting white blood cells, weak antibody responses and poor production of a protein that is vital for <a href="https://doi.org/10.1073/pnas.1019378108" target="_blank">combating viral infection and modulating the immune response</a>.</p><p><a href="https://doi.org/10.1371/journal.pone.0184976" target="_blank" rel="noopener noreferrer">In another study</a>, mice were fed <em>Lactobacillus</em> bacteria, commonly used as probiotic in fermented food. These microbes reduced the severity of influenza infection. The <em>Lactobacillus</em>-treated mice did not lose weight and had only mild lung damage compared with untreated mice. Similarly, others have found that treatment of mice with <em>Lactobacillus</em> protects against different <a href="https://doi.org/10.1038/srep04638" target="_blank" rel="noopener noreferrer">subtypes of</a> <a href="https://doi.org/10.1038/s41598-017-17487-8" target="_blank" rel="noopener noreferrer">influenza</a> <a href="https://doi.org/10.1371/journal.ppat.1008072" target="_blank" rel="noopener noreferrer">virus</a> and human respiratory syncytial virus – the <a href="https://doi.org/10.1038/s41598-019-39602-7" target="_blank" rel="noopener noreferrer">major cause of viral bronchiolitis and pneumonia in children</a>.</p>
Chronic Disease and Microbes<p>Patients with chronic illnesses including Type 2 diabetes, obesity and cardiovascular disease exhibit a hyperactive immune system that fails to recognize a harmless stimulus and is linked to an altered gut microbiome.</p><p>In these chronic diseases, the gut microbiome lacks bacteria that activate <a href="https://doi.org/10.1126/science.1198469" target="_blank" rel="noopener noreferrer">immune cells</a> that block the response against harmless bacteria in our guts. Such alteration of the gut microbiome is also observed in <a href="https://doi.org/10.1073/pnas.1002601107" target="_blank" rel="noopener noreferrer">babies delivered by cesarean section</a>, individuals consuming a poor <a href="https://doi.org/10.1038/nature12820" target="_blank" rel="noopener noreferrer">diet</a> and the <a href="https://doi.org/10.1038/nature11053" target="_blank" rel="noopener noreferrer">elderly</a>.</p><p>In the U.S., 117 million individuals – about half the adult population – <a href="https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/" target="_blank" rel="noopener noreferrer">suffer from Type 2 diabetes, obesity, cardiovascular disease or a combination of them</a>. That suggests that half of American adults carry a faulty microbiome army.</p><p>Research in my laboratory focuses on identifying gut bacteria that are critical for creating a balanced immune system, which fights life-threatening bacterial and viral infections, while tolerating the beneficial bacteria in and on us.</p><p>Given that diet affects the diversity of bacteria in the gut, <a href="https://www.umassmed.edu/nutrition/melody-trial-info/" target="_blank" rel="noopener noreferrer">my lab studies show how diet can be used</a> as a therapy for chronic diseases. Using different foods, people can shift their gut microbiome to one that boosts a healthy immune response.</p><p>A fraction of patients infected with SARS-CoV-2, the virus that causes COVID-19 disease, develop severe complications that require hospitalization in intensive care units. What do many of those patients have in common? <a href="https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm" target="_blank" rel="noopener noreferrer">Old age</a> and chronic diet-related diseases like obesity, Type 2 diabetes and cardiovascular disease.</p><p><a href="http://doi.org/10.1016/j.jada.2008.12.019" target="_blank" rel="noopener noreferrer">Black and Latinx people are disproportionately affected by obesity, Type 2 diabetes and cardiovascular disease</a>, all of which are linked to poor nutrition. Thus, it is not a coincidence that <a href="https://www.cdc.gov/mmwr/volumes/69/wr/mm6933e1.htm" target="_blank" rel="noopener noreferrer">these groups have suffered more deaths from COVID-19</a> compared with whites. This is the case not only in the U.S. but also <a href="https://www.washingtonpost.com/world/europe/blacks-in-britain-are-four-times-as-likely-to-die-of-coronavirus-as-whites-data-show/2020/05/07/2dc76710-9067-11ea-9322-a29e75effc93_story.html" target="_blank" rel="noopener noreferrer">in Britain</a>.</p>
Discovering Microbes That Predict COVID-19 Severity<p>The COVID-19 pandemic has inspired me to shift my research and explore the role of the gut microbiome in the overly aggressive immune response against SARS-CoV-2 infection.</p><p>My colleagues and I have hypothesized that critically ill SARS-CoV-2 patients with conditions like obesity, Type 2 diabetes and cardiovascular disease exhibit an altered gut microbiome that aggravates <a href="https://theconversation.com/exercise-may-help-reduce-risk-of-deadly-covid-19-complication-ards-136922" target="_blank" rel="noopener noreferrer">acute respiratory distress syndrome</a>.</p><p>Acute respiratory distress syndrome, a life-threatening lung injury, in SARS-CoV-2 patients is thought to develop from a <a href="http://doi.org/10.1016/j.cytogfr.2020.05.003" target="_blank" rel="noopener noreferrer">fatal overreaction of the immune response</a> called a <a href="https://theconversation.com/blocking-the-deadly-cytokine-storm-is-a-vital-weapon-for-treating-covid-19-137690" target="_blank" rel="noopener noreferrer">cytokine storm</a> <a href="http://doi.org/10.1016/S2213-2600(20)30216-2" target="_blank" rel="noopener noreferrer">that causes an uncontrolled flood</a> <a href="http://doi.org/10.1016/S2213-2600(20)30216-2" target="_blank" rel="noopener noreferrer">of immune cells into the lungs</a>. In these patients, their own uncontrolled inflammatory immune response, rather than the virus itself, causes the <a href="http://doi.org/10.1007/s00134-020-05991-x" target="_blank" rel="noopener noreferrer">severe lung injury and multiorgan failures</a> that lead to death.</p><p>Several studies <a href="https://doi.org/10.1016/j.trsl.2020.08.004" target="_blank" rel="noopener noreferrer">described in one recent review</a> have identified an altered gut microbiome in patients with COVID-19. However, identification of specific bacteria within the microbiome that could predict COVID-19 severity is lacking.</p><p>To address this question, my colleagues and I recruited COVID-19 hospitalized patients with severe and moderate symptoms. We collected stool and saliva samples to determine whether bacteria within the gut and oral microbiome could predict COVID-19 severity. The identification of microbiome markers that can predict the clinical outcomes of COVID-19 disease is key to help prioritize patients needing urgent treatment.</p><p><a href="https://doi.org/10.1101/2021.01.05.20249061" target="_blank" rel="noopener noreferrer">We demonstrated</a>, in a paper which has not yet been peer reviewed, that the composition of the gut microbiome is the strongest predictor of COVID-19 severity compared to patient's clinical characteristics commonly used to do so. Specifically, we identified that the presence of a bacterium in the stool – called <em>Enterococcus faecalis</em>– was a robust predictor of COVID-19 severity. Not surprisingly, <em>Enterococcus faecalis</em> has been associated with <a href="https://doi.org/10.1053/j.gastro.2011.05.035" target="_blank" rel="noopener noreferrer">chronic</a> <a href="https://doi.org/10.1016/S0002-9440(10)61172-8" target="_blank" rel="noopener noreferrer">inflammation</a>.</p><p><em>Enterococcus faecalis</em> collected from feces can be grown outside of the body in clinical laboratories. Thus, an <em>E. faecalis</em> test might be a cost-effective, rapid and relatively easy way to identify patients who are likely to require more supportive care and therapeutic interventions to improve their chances of survival.</p><p>But it is not yet clear from our research what is the contribution of the altered microbiome in the immune response to SARS-CoV-2 infection. A recent study has shown that <a href="https://doi.org/10.1101/2020.12.11.416180" target="_blank" rel="noopener noreferrer">SARS-CoV-2 infection triggers an imbalance in immune cells</a> called <a href="https://doi.org/10.1111/imr.12170" target="_blank" rel="noopener noreferrer">T regulatory cells that are critical to immune balance</a>.</p><p>Bacteria from the gut microbiome are responsible for the <a href="https://doi.org/10.7554/eLife.30916.001" target="_blank" rel="noopener noreferrer">proper activation</a> <a href="https://doi.org/10.1126/science.1198469" target="_blank" rel="noopener noreferrer">of those T-regulatory</a> <a href="https://doi.org/10.1038/nri.2016.36" target="_blank" rel="noopener noreferrer">cells</a>. Thus, researchers like me need to take repeated patient stool, saliva and blood samples over a longer time frame to learn how the altered microbiome observed in COVID-19 patients can modulate COVID-19 disease severity, perhaps by altering the development of the T-regulatory cells.</p><p>As a Latina scientist investigating interactions between diet, microbiome and immunity, I must stress the importance of better policies to improve access to healthy foods, which lead to a healthier microbiome. It is also important to design culturally sensitive dietary interventions for Black and Latinx communities. While a good-quality diet might not prevent SARS-CoV-2 infection, it can treat the underlying conditions related to its severity.</p><p><em><a href="https://theconversation.com/profiles/ana-maldonado-contreras-1152969" target="_blank">Ana Maldonado-Contreras</a> is an assistant professor of Microbiology and Physiological Systems at the University of Massachusetts Medical School.</em></p><p><em>Disclosure statement: Ana Maldonado-Contreras receives funding from The Helmsley Charitable Trust and her work has been supported by the American Gastroenterological Association. She received The Charles A. King Trust Postdoctoral Research Fellowship. She is also member of the Diversity Committee of the American Gastroenterological Association.</em></p><p><em style="">Reposted with permission from <a href="https://theconversation.com/a-healthy-microbiome-builds-a-strong-immune-system-that-could-help-defeat-covid-19-145668" target="_blank" rel="noopener noreferrer" style="">The Conversation</a>. </em></p>
By Jeff Masters, Ph.D.
The New Climate War: the fight to take back our planet is the latest must-read book by leading climate change scientist and communicator Michael Mann of Penn State University.
- 12 New Books Explore Fresh Approaches to Act on Climate Change ... ›
- Dr. Michael Mann on Climate Denial: 'It's Impaired Our Ability to ... ›